Market research
326030.KO SK Biopharmaceuticals Co., Ltd
KO KRW Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 6T
- P/E ratio
- 14.63
- Analyst target
- 130500
- Dividend yield
- Not available
- Beta
- 0.7
Profile
Instrument facts
- Exchange
- KO
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KR7326030004
- Market cap
- 6T
- P/E ratio
- 14.63
- Analyst target
- 130500
- Dividend yield
- Not available
- Beta
- 0.7
About
About SK Biopharmaceuticals Co., Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.
Research context
SK Biopharmaceuticals Co., Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 326030.KO discussion.
5 years, 6 months ago
SK Biopharmaceuticals Co., Ltd is currently in a long term downtrend where the price is trading 6.2% below its 200 day moving average.
From a valuation standpoint, the stock is 3234.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 285.7.
Based on the above factors, SK Biopharmaceuticals Co., Ltd gets an overall score of 0/5.